Pharmacogenomics of Drug Metabolism and Pharmacokinetics

Dear Colleagues,

Pharmacogenomics is a key influencer in how medications and health supplements are broken down or transported across the membrane. Drug-metabolizing enzymes or transporters contribute to drug plasma concentrations, which can in turn determine the clinical success of a drug. Human cytochrome P450 (CYP) and uridine diphosphate–glucuronosyltransferase (UGT) enzymes are examples of major drug-metabolizing enzymes that are susceptible to genetic variations. The genotypes of the enzymes and transporters are the primary determinants of metabolic and transport phenotypes. Since plasma concentrations can determine the therapeutic success/failure or the extent of adverse drug effects, polymorphisms in CYP, UGTs, or other drug-metabolizing enzymes or transporters can significantly impact the therapeutic or toxic outcomes from treatment regimens. This Special Issue invites manuscripts that focus on the pharmacogenomics of drug-metabolizing enzymes and transporters applicable to both synthetic medications and natural health supplements. The relationship between pharmacogenomics and pharmacokinetics in the context of drug efficacy, therapeutic failure, or adverse drug effects is a particular area of interest. Manuscripts which highlight the pharmacogenomic databases and guidelines related to the genes involved in pharmacokinetics will also be considered.

Dr. Subrata Deb
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• pharmacogenomics
• drug metabolism and drug-metabolizing enzymes
• cytochrome P450 enzymes
• transporters
• adverse drug effects
• therapeutic failure
• genotype and phenotype
• pharmacokinetics
• personalized medicine
• pharmacogenomic databases and guidelines